Total
0
Shares
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley
CEO, Dr Jackie Fairley
Source: Dr Jackie Fairley/LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Starpharma (SPL) signs a deal with ADMENTA Italia Group for its VIRALEZE treatment to be distributed in Italy
  • Under the agreement, Starpharma will supply the VIRALEZE, with ADMENTA responsible for distribution, sales, and marketing of the product in Italy
  • The nasal spray is expected to be available to Italian consumers in stores and via LloydsFarmacia’s online platform this quarter
  • The antiviral nasal spray is now registered in Europe and India and is available in certain markets online
  • Starpharma’s shares are up 1.67 per cent to trade at $1.22

Starpharma (SPL) has signed a deal for its VIRALEZE treatment to be distributed in Italy.

VIRALEZE is an antiviral nasal spray which provides a physical barrier to trap and inactivate viruses, including SARS-CoV-2, which has been proven to have a greater than 99.9 per cent inactivation of the Delta variant of COVID-19.

The sales and distribution agreement for the antiviral nasal spray is with ADMENTA Italia Group, a pharmaceutical retail and wholesale distribution company, considered the third largest in Europe.   

ADMENTA operates over 260 pharmacies under its LloydsFarmacia brand. ADMENTA employs around 1400 people in Italy across both wholesale and retail, supplying over 2500 pharmacies, parapharmacies, drug stores and hospitals.

Under the agreement, Starpharma will supply VIRALEZE, with ADMENTA responsible for distribution, sales, and marketing of the product in Italy.

Starpharma CEO, Dr Jackie Fairley, was pleased to have signed this deal.

“We are very pleased to have partnered with ADMENTA in Italy and we look forward to having VIRALEZE available soon to Italian consumers, through pharmacies as well as through the leading LloydsFarmacia online platform.”

VIRALEZE is expected to be available to Italian consumers in stores and via LloydsFarmacia’s online platform this quarter.

The antiviral nasal spray is now registered in Europe and India and is available in certain markets online.

Starpharma’s shares were up 1.67 per cent to trade at $1.22 at 10:42 am AEDT.

SPL by the numbers
More From The Market Herald

" Recce Pharmaceuticals (ASX:RCE) receives positive safety data from second cohort of Phase I Clinical Trial

Recce Pharmaceuticals (ASX:RCE) has released positive safety data from its second cohort of subjects for its…
Virtus Health (ASX:VRT) - CEO & Managing Director, Kate Munnings

" Virtus Health (ASX:VRT) has non-urgent elective surgeries suspended in NSW & VIC

Virtus Health (ASX:VRT) has had its non-urgent elective surgeries suspended in NSW and Victoria as the…

" Creso Pharma (ASX:CPH) appoints William Lay as CEO & MD

Creso Pharma (ASX:CPH) has strengthened its board with the appointment of William Lay as CEO and…

" Monash IVF Group (ASX:MVF) suspends certain procedures in Victoria

Following new health orders in Victoria, Monash IVF Group (ASX:MVF) says non-urgent surgery protocols will disrupt…